"Recognitions such as this greatly fuel our efforts, motivate us, and encourage us to continue on our mission to end the preventable blindness associated with diabetic retinopathy." — Jason Crawford, CEO
Pensacola, FL (PRWEB) September 18, 2015
IRIS: Intelligent Retinal Imaging Systems™ has been named to the prestigious 2015 Florida Companies to Watch award list by the economic development group GrowFL, in association with the Edward Lowe Foundation.
IRIS’ entrepreneurial leadership, innovative product and services, strong community involvement, and competitive market position were among several factors that led to its selection from more than 500 nominees.
The Florida Companies to Watch award list is comprised of 50 statewide businesses expected to see significant growth over the next several years. “This is a strong group of companies that deserve the special recognition given annually to the state's top second stage companies,” said Dr. Tom O’Neal, executive director of the Florida Economic Gardening Institute and associate vice president for the University of Central Florida’s Oﬃce of Research and Commercialization. Second-stage companies are defined as those with six to 99 full-time employees and between $750,000 and $50 million in annual revenue.
“These stand-out companies are all led by entrepreneurs, and have demonstrated their capacity and intent to grow,” said Dr. O’Neal. “They also all have critical intellectual property or a niche position that gives them a competitive edge in their markets,” he said.
The 50 companies on the list generated a total of more than $1.2 billion in revenue and added nearly 1,000 employees between 2011 and 2014. Together, the businesses project a 23 percent increase in revenue and 19 percent increase in job growth in 2015.
“Grow Florida is a critical component of Florida’s economic development strategy and entrepreneurial ecosystem. Receiving this distinguished award means a great deal to all of us at IRIS,” said Jason Crawford, CEO of IRIS. “Recognitions such as this greatly fuel our efforts, motivate us, and encourage us to continue on our mission to end the preventable blindness associated with diabetic retinopathy.”
IRIS is an FDA-cleared, cloud-based service that has improved quality, expanded access, and reduced costs for Diabetic Retinopathy exams across the United States. Its team of physicians, technicians, and change management experts seek to partner with forward-thinking providers and payers alike to enhance quality outcomes and create a better healthcare system.
IRIS, and other companies named to the list, will be honored at the awards ceremony November 5th, at Rock Live, Universal CityWalk, Orlando.
For more information about IRIS, visit retinalscreenings.com